Abstract
The present study evaluated the effects of histamine H3 receptor agonist BP 2.94 or H3 receptor antagonist carboperamide (MR 16155) given by oral route on sleep and waking in rats surgically prepared for long-term recordings.
BP 2.94 produced a significant increase of slow-wave sleep (SWS) that was related to slight decreases of waking, light sleep, and REM sleep. Carboperamide significantly increased waking and decreased SWS and REM sleep. Pretreatment with carboperamide prevented the effect of BP 2.94 on SWS.
It is suggested that the effects of BP 2.94 or carboperamide on sleep and waking could depend on changes in the availability of histamine at the postsynaptic H1 receptor. Alternatively, activation or blockade of the H3 heteroreceptors found in the central catecholamine, indolamine, and acetylcholine nerve endings could inhibit or increase the release of noradrenaline, serotonin, dopamine, and acetylcholine. This would secondarily result in changes of sleep variables.
Similar content being viewed by others
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Monti, J., Jantos, H., Ponzoni, A. et al. Sleep and Waking during Acute Histamine H3 Agonist BP 2.94 or H3 Antagonist Carboperamide (MR 16155) Administration in Rats. Neuropsychopharmacol 15, 31–35 (1996). https://doi.org/10.1016/0893-133X(95)00151-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1016/0893-133X(95)00151-3
Keywords
This article is cited by
-
Samelisant (SUVN-G3031), a potent, selective and orally active histamine H3 receptor inverse agonist for the potential treatment of narcolepsy: pharmacological and neurochemical characterisation
Psychopharmacology (2021)
-
Fexofenadine Induced Spontaneous Ejaculations: Rare Case with Literature Review
SN Comprehensive Clinical Medicine (2021)
-
Histamine N-methyltransferase regulates aggression and the sleep-wake cycle
Scientific Reports (2017)
-
Acute wake‐promoting actions of JNJ‐5207852, a novel, diamine‐based H3 antagonist
British Journal of Pharmacology (2004)